Board of Directors

The Board and executive management team include senior and experienced individuals with pharmaceutical and financial backgrounds and general management experience: Alan Frame (Chairman), David Laskow-Pooley (Chief Executive Officer), Clive Booles (Research & Development Director), Christopher Duffy (non-executive director) and Mark Ashurst (non-executive director).

Alan Frame - Chairman

Alan Frame spent 30 years in newspaper publishing before founding Property Internet, an early pioneer of the property search sites. Property Internet floated on the London Stock Exchange, the first such company to achieve a listing. He was previously managing director of Liberty Publishing and is currently a non-executive director of ProtoPharma (a subsidiary of LondonPharma).

Alan in his role as a reputation and public relations advisor has advised clients as diverse as the Conservative Party, Sports Direct, the Timiş Corporation, Express Newspapers and members of the opposition to Saddam Hussein during the war with Iraq. He co-founded LondonPharma in 2007. Alan is involved with several charities as a trustee of Street Child, a patron of Miracles and a fundraiser for the wounded soldiers' charity, Coming Home. He is former honorary president of Children of Chernobyl Lifeline. 

David Laskow-Pooley - Chief Executive Officer

David Laskow-Pooley is a pharmacist with more than 35 years experience and proven track record in the pharmaceutical industry with the major international corporations including GlaxoSmithKline, Abbott and Amersham and emerging enterprises including OSI Pharmaceuticals. He has held senior posts in development, operations and general management, and involved in the development and launching of products in cancer (Tarceva® to treat lung cancer, the brachytherapy RAPID Strand® to treat prostate cancer), cardiovascular disease (Hytrin® to treat high blood pressure and enlarged prostate) and anti-infectives (Clarithromycin® to treat bacterial infections). He has created both spin-outs and start-ups during his career.

David is Chairman and non-executive director of OBN, a membership organisation that supports and brings together the UK's emerging life sciences companies. Through this organisation and his other interests he has access to an extensive network of experts and specialist development companies. In March 2015 David was appointed to the Board of Seattle-based cancer immunotherapy company, TapImmune Inc, which is developing innovative vaccines for the treatment of cancer and infectious diseases. 

Clive Booles - Research & Development Director

Clive Booles has more than 45 years experience and expertise in formulation and development of spray delivery technology with major companies including 3M Healthcare, Fisons (now Sanofi) and Sosei. He was responsible for inhalation projects at 3M (mainly contract development and manufacture for major multinationals) and formed, recruited and trained the inhalation group at Sanofi. Numerous products created include the Intal® MDI range (asthma prevention), Bricanyl® (bronchodilator) and Pulmicort® (inhaled steroid). Clive has a degree in chemistry and physics and is a Chartered Scientist, a Chartered Chemist, a Member of the Royal Society of Chemistry, a Chartered Physicist and Member of the Institute of Physics.

Non-executive directors

Christopher Duffy - non-executive director

Christopher Duffy has been a London-based partner at global law firm Clyde & Co since 1989 and where he founded the corporate department. He has particular experience of the financial, food and resource sectors and covers cross-border transactions, M&A, joint ventures and quoted company work. He is also a non-executive director of Moneynet.

Mark Ashurst - non-executive director

Mark Ashurst is a qualified barrister and chartered accountant with a distinguished career spanning over 20 years in the City of London. He developed a broad range of corporate finance and broking skills working for BZW Limited, Hoare Govett Limited and Canaccord Adams and advised both UK and overseas listed companies. He has significant expertise in IPOs, fund raising and mergers and acquisitions. Mark is currently Chief Financial Officer of African Petroleum Corp Ltd and a director of Eastern Petroleum Corp Ltd. He is Member of the Institute of Chartered Accountants In England & Wales.

Updated: 30March2015

Print this page